In line with the EoI doc, purposes needs to be submitted earlier than June 17 by means of e mail
Hyderabad: The Defence Analysis and Growth Organisation (DRDO), which developed 2-Deoxy-D-Glucose (2-DG), a drug used for therapy of COVID-19 sufferers, has referred to as for Expression of Curiosity (EoI) to switch the expertise to Indian pharmaceutical industries for manufacturing.
2-DG was developed by the Institute of Nuclear Drugs and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories.
Scientific trial outcomes have proven that this molecule helps in sooner restoration of hospitalised sufferers and reduces supplemental oxygen dependence.
Larger proportion of sufferers handled with 2-DG confirmed RT-PCR unfavourable conversion in COVID sufferers.
In line with the EoI doc, purposes needs to be submitted earlier than June 17 by means of e mail.
“The EoI submitted by industries might be scrutinised by a Technical Evaluation Committee (TAC). Solely as much as 15 industries might be given ToT on their capabilities, technical hand holding functionality of DRDO and on First Come First Served Foundation,” it mentioned.
The bidders ought to have a Drug license to fabricate Lively Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good manufacturing Practices) certification amongst others.
Laboratory synthesis course of for 2-DG has been developed utilizing D-Glucose as beginning materials.
The synthesis course of consists of conversion of D-Glucose to 2-DG by means of 5 chemical response steps adopted by purification.
The method has been established at batch scale (100g) and pilot plant scale (500g) and needed patents have been filed by DRDO on this regard, the Defence physique mentioned.